ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women; Nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization; and OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone41-22-552-3840
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees43
Next Earnings Date11/14/2019 (Estimated)
OptionableNot Optionable
Obseva (NASDAQ:OBSV) Frequently Asked Questions
What is Obseva's stock symbol?
Obseva trades on the NASDAQ under the ticker symbol "OBSV."
How were Obseva's earnings last quarter?
Obseva SA (NASDAQ:OBSV) announced its quarterly earnings results on Wednesday, August, 7th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.58) by $0.22. View Obseva's Earnings History.
When is Obseva's next earnings date?
What price target have analysts set for OBSV?
4 brokers have issued 1 year price objectives for Obseva's stock. Their forecasts range from $16.00 to $44.00. On average, they expect Obseva's stock price to reach $32.67 in the next twelve months. This suggests a possible upside of 350.0% from the stock's current price. View Analyst Price Targets for Obseva.
What is the consensus analysts' recommendation for Obseva?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Obseva in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Obseva.
What are Wall Street analysts saying about Obseva stock?
Here are some recent quotes from research analysts about Obseva stock:
- 1. According to Zacks Investment Research, "ObsEva SA is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics for woman's reproductive health and pregnancy. ObsEva SA is headquartered in Geneva, Switzerland. " (10/22/2019)
- 2. HC Wainwright analysts commented, "Valuation methodology, risks and uncertainties. Our risk-adjusted net present value (rNPV) approach ascribes $1.9B to linzagolix (formerly to nolasiban. We utilize an 85% probability of approval for linzagolix and 75% for nolasiban." (9/4/2019)
Has Obseva been receiving favorable news coverage?
Media headlines about OBSV stock have trended somewhat positive on Tuesday, InfoTrie reports. The research group identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Obseva earned a daily sentiment score of 1.8 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for Obseva.
Are investors shorting Obseva?
Obseva saw a drop in short interest in September. As of September 30th, there was short interest totalling 290,800 shares, a drop of 33.4% from the August 30th total of 436,900 shares. Based on an average trading volume of 44,400 shares, the days-to-cover ratio is presently 6.5 days. Approximately 1.5% of the company's stock are short sold. View Obseva's Current Options Chain.
Who are some of Obseva's key competitors?
Some companies that are related to Obseva include Ironwood Pharmaceuticals (IRWD), Eidos Therapeutics (EIDX), Madrigal Pharmaceuticals (MDGL), Opko Health (OPK), Radius Health (RDUS), BELLUS Health (BLUSF), Enanta Pharmaceuticals (ENTA), Zymeworks (ZYME), Turning Point Therapeutics (TPTX), Dicerna Pharmaceuticals (DRNA), Endo International (ENDP), ArQule (ARQL), Innoviva (INVA), Gossamer Bio (GOSS) and Esperion Therapeutics (ESPR).
What other stocks do shareholders of Obseva own?
Who are Obseva's key executives?
Obseva's management team includes the folowing people:
- Dr. Ernest Loumaye, Co-Founder, CEO & Director (Age 67)
- Mr. Timothy M. Adams, Chief Financial Officer (Age 59)
- Dr. Jean-Pierre Gotteland Ph.D., Chief Scientific Officer and Head of R&D (Age 54)
- Mr. Mario Vincent Corso, Sr. Director of Investor Relations
- Dr. Elke Bestel M.D., Chief Medical Officer & Head of Pharmacovigilance (Age 53)
When did Obseva IPO?
(OBSV) raised $98 million in an initial public offering (IPO) on Thursday, January 26th 2017. The company issued 6,500,000 shares at $14.00-$16.00 per share. Credit Suisse, Jefferies and Leerink Partners served as the underwriters for the IPO.
Who are Obseva's major shareholders?
Obseva's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Wedbush Securities Inc. (0.09%).
Which major investors are buying Obseva stock?
OBSV stock was acquired by a variety of institutional investors in the last quarter, including Wedbush Securities Inc..
How do I buy shares of Obseva?
Shares of OBSV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Obseva's stock price today?
One share of OBSV stock can currently be purchased for approximately $7.26.
How big of a company is Obseva?
Obseva has a market capitalization of $330.16 million. The company earns $-76,720,000.00 in net income (profit) each year or ($1.91) on an earnings per share basis. Obseva employs 43 workers across the globe.View Additional Information About Obseva.
What is Obseva's official website?
How can I contact Obseva?
Obseva's mailing address is Chemin des Aulx 12 Plan-les-Ouates, Geneva V8, 1228. The company can be reached via phone at 41-22-552-3840 or via email at [email protected]
MarketBeat Community Rating for Obseva (NASDAQ OBSV)
MarketBeat's community ratings are surveys of what our community members think about Obseva and other stocks. Vote "Outperform" if you believe OBSV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OBSV will underperform the S&P 500 over the long term. You may vote once every thirty days.
